EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Aikaterini Motso, Benjamin Pelcman, Anastasia Kalinovich, Nour Aldin Kahlous, Muhammad Hamza Bokhari, Nodi Dehvari, Carina Halleskog, Erik Waara, Jasper de Jong, Elizabeth Cheesman, Christine Kallenberg, Gopala Krishna Yakala und 36 weitere

Cell · 2025

DOI: 10.1016/j.cell.2025.05.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2025. Verfasst von Aikaterini Motso und 47 weiteren Autor:innen. Beteiligte Einrichtung: Atrogi AB, Stockholm, Sweden; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden; Department of …. Hauptthemen laut MEDLINE: Obesity, Diabetes Mellitus, Type 2, G-Protein-Coupled Receptor Kinase 2, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Society for Medical Research, Knut and Alice Wallenberg Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biased agonism of G protein-coupled receptors (GPCRs) offers potential for safer medications. Current efforts have explored the balance between G proteins and β-arrestin; however, other transducers like GPCR kinases (GRKs) remain understudied. GRK2 is essential for β2 adrenergic receptor (β2AR)-mediated glucose uptake, but β2AR agonists are considered poor clinical candidates for glycemic management due to Gs/cyclic AMP (cAMP)-induced cardiac side effects and β-arrestin-dependent desensitization. Using ligand-based virtual screening and chemical evolution, we developed pathway-selective agonists of β2AR that prefer GRK coupling. These compounds perform well in preclinical models of hyperglycemia and obesity and demonstrate a lower potential for cardiac and muscular side effects compared with standard β2-receptor agonists and incretin mimetics, respectively. Furthermore, the lead candidate showed favorable pharmacokinetics and was well tolerated in a placebo-controlled clinical trial. GRK-biased β2AR partial agonists are thus promising oral alternatives to injectable incretin mimetics used in the treatment of type 2 diabetes and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityDiabetes Mellitus, Type 2G-Protein-Coupled Receptor Kinase 2Adrenergic beta-2 Receptor AgonistsAdrenergic AgonistsHumansAnimalsReceptors, Adrenergic, beta-2MiceMale

Stichwörter der Autor:innen

BRETGLP-1GPCRGRKbeta-2 agonistsbiased agonismdiabetesmetabolismobesityskeletal muscle

Substanzen

Receptors, Adrenergic, beta-2G-Protein-Coupled Receptor Kinase 2Adrenergic beta-2 Receptor AgonistsAdrenergic Agonists

Autor:innen und Institutionen

  • Atrogi AB, Stockholm, Sweden; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden; Department of Physiology & Pharmacology, Section for Personalized Medicine and Drug…
  • Atrogi AB, Stockholm, Sweden.
  • Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
  • Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
  • Cardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Queensland University of Technology…
  • Department of Physiology & Pharmacology, Section for Personalized Medicine and Drug Development, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Swedish Society for Medical Research
  • Knut and Alice Wallenberg Foundation
  • Novo Nordisk Foundation
  • German Research Foundation
  • Swedish Research Council

Zitieren

APA

Motso, A., Pelcman, B., Kalinovich, A., Kahlous, N. A., Bokhari, M. H., Dehvari, N., Halleskog, C., Waara, E., de Jong, J., Cheesman, E., Kallenberg, C., Yakala, G. K., Murad, P., Wetterdal, E., Andersson, P., van Beek, S., Sandström, A., Alleluia, D. N., Talamonti, E., …, & Bengtsson, T. (2025). GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell. https://doi.org/10.1016/j.cell.2025.05.042

Vancouver

Motso A, Pelcman B, Kalinovich A, Kahlous NA, Bokhari MH, Dehvari N, et al. GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell. 2025. doi:10.1016/j.cell.2025.05.042

BibTeX
@article{Motso2025,
  author = {Motso, Aikaterini and Pelcman, Benjamin and Kalinovich, Anastasia and Kahlous, Nour Aldin and Bokhari, Muhammad Hamza and Dehvari, Nodi and Halleskog, Carina and Waara, Erik and de Jong, Jasper and Cheesman, Elizabeth and Kallenberg, Christine and Yakala, Gopala Krishna and Murad, Praerona and Wetterdal, Erika and Andersson, Pia and van Beek, Sten and Sandström, Anna and Alleluia, Diane Natacha and Talamonti, Emanuela and Youhanna, Sonia and Sabatier, Pierre and Koenig, Claire and Willems, Sabine and Kemas, Aurino M and Hutchinson, Dana S and Ham, Seungmin and Grätz, Lukas and Voss, Jan and Marchan-Alvarez, Jose G and Priede, Martins and Jaunsleine, Krista and Spura, Jana and Kovada, Vadims and Supe, Linda and Stoddart, Leigh A and Holliday, Nicholas D and Newton, Phillip T and Pillon, Nicolas J and Schulte, Gunnar and Summers, Roger J and Mutule, Ilga and Suna, Edgars and Olsen, Jesper V and Molenaar, Peter and Carlsson, Jens and Lauschke, Volker M and Wright, Shane C and Bengtsson, Tore},
  title = {GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity},
  journal = {Cell},
  year = {2025},
  doi = {10.1016/j.cell.2025.05.042}
}
Kostenlos starten →